Therefore, in thefuture, it may be possible to combine these drugs or apply them sequentiallydepending on the expression patterns of USP7, CCDC6, and EZH2 in individual cases ofprostate cancer to provide novel forms of customized therapy. Here, EZH2 is linked to cancer.